Navigation Links
JAZZ PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2013 FINANCIAL RESULTS
Date:8/6/2013

er of 2013 net interest expense was $7.1 million, and the loss on extinguishment and modification of debt was $3.7 million.  As of June 30, 2013, our cash and cash equivalents were $504.3 million, and the balance of our term loans was $552.3 million. The balance of cash and cash equivalents increased from December 31, 2012 primarily due to the cash generated from our business and the net proceeds of the new term loans, offset in part by funds used to repurchase our ordinary shares under our share repurchase program and increases in working capital.

In May 2013, our board of directors authorized the use of up to $200 million to repurchase the company's ordinary shares.  As of June 30, 2013, we had repurchased 846,197 shares for $53.6 million at an average cost of $63.32 per share. 

On June 13, 2013, we amended our credit agreement, increased the principal amount of the term loans to $557.2 million, an increase of $100 million from the remaining principal amount of the original term loans, and increased the revolving credit facility from $100 million to $200 million.  The interest rate on our term loans is currently 3.5% based on a 0.75% LIBOR floor plus a margin of 2.75% per annum, compared to an interest rate of 5.25% prior to the amended credit agreement. Our revolving credit facility remains undrawn.

During the fourth quarter of 2012, the company sold its women's health business.  Financial results from the women's health business are reported as discontinued operations for the 2012 periods.

2013 Financial Guidance Jazz Pharmaceuticals is providing the following updated 2013 guidance:Revenues

 

$860-$880 million

 Total Net Product Sales

 

$853-$873 million

 -Xyrem Net Sales

-Erwinaze/Erwinase Net Sales

$560-$570 million

$170-$180 millionAdjusted Gross Margin %1,3

88-90% Adjusted Combined SG&A an
'/>"/>

SOURCE Jazz Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Cumberland Pharmaceuticals Reports Second Quarter Financial Results
2. Inovio Pharmaceuticals Responds to Market Activity
3. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
4. Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Bausch + Lomb
5. Avanir Pharmaceuticals to Participate in Two Conferences in August
6. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
7. AcelRx Pharmaceuticals to Present at Canaccord Genuity 33rd Annual Growth Conference
8. Isis Pharmaceuticals Reports Data From a Phase 2 Study of Isis-CRP Rx in Patients with Rheumatoid Arthritis
9. Intercept Pharmaceuticals to Present at the Wedbush Securities Life Sciences Management Access Conference
10. GW Pharmaceuticals Announces Results of MS Spasticity Study Confirming Sativex Has No Long-Term Negative Effect on Cognition
11. GW Pharmaceuticals plc Reports 2013 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex ... it expects to report results for the fourth quarter ... release announcing the results is scheduled for release after ... http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management will hold a conference ... for the fourth quarter and twelve months ended December ...
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new ... targeting guide with accompanying instrumentation to place and insert ... to the soft tissue (e.g. ligament) repair or reconstruction ... repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ... the anatomical reduction (spacing) of the scaphoid and lunate ...
(Date:1/14/2014)... 2014   Oligomerix, Inc. , a privately ... therapeutics for Alzheimer,s disease (AD) and related neurodegenerative ... headquarters to Valhalla, NY ... agreement for additional laboratory space at New York ... on the development of small molecule drugs aimed ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... August 27 , - Oralair(R) Grasses 300IR Highly ... Allergen Challenge Chamber, Stallergenes S.A. announces the highly ... Challenge Chamber (ACC)., The study on Oralair(R) Grasses ... different treatment durations: 1 week, 1 month,2 and 4 ...
... INDIANAPOLIS, Aug. 26 Semafore Pharmaceuticals Inc.,announced data ... in Cancer in Washington, D.C., showing additional antiangiogenic,activity ... both VEGF and Bv8 signaling., PI3K is ... /mTOR pathway that,has been shown to play a ...
Cached Medicine Technology:Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 2Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 3SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 2SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... ... health movement, is now a featured expert on searchbloodsugar.com, a new informational Web site devoted ... ... Julian Whitaker, MD , a founder of the alternative health movement, is now a featured ...
... ... now be performed at the doctor,s office to indicate the condition of the arteries in the ... Los Angeles (PRWEB) June 16, ... for use in doctors, offices. "This is state of the art imaging," says Dr. Joseph ...
... ... Center, even though the iLASIK™ Procedure is not without risk, wearing contacts has its own ... more common when compared to the iLASIK procedure. , ... New York, NY (PRWEB) June 16, 2009 -- Board Certified Eye ...
... Calif., June 16 As Congressional committees begin to ... and debate intensifies, the latest Kaiser health tracking poll finds ... , A solid majority of the American people (61%) ... ever given the country,s economic problems); sizeable majorities support key ...
... Center Opens at LA,s Landmark Burke Williams as Part of Growing ... Calif., June 15 After walking into Burke Williams Day Spa,s ... water and fresh fruit, to locker room and quiet room for ... of Spa 7 Laser & Cosmetic Center. This is where ...
... 2009) A low cellular level of a tiny ... breast cancer in mouse models of the disease, according ... Measuring levels of this so-called microRNA, which is ... more accurately predict the likelihood of metastasis (which accounts ...
Cached Medicine News:Health News:Dr. Julian Whitaker Featured on Searchbloodsugar.com 2Health News:Dr. Julian Whitaker Featured on Searchbloodsugar.com 3Health News:Breakthrough Testing For Early Heart Disease - In the Doctor's Office 2Health News:Kevin Niksarli, M.D. of Manhattan Lasik Center Reviews Pros and Cons of Contact Lenses vs. iLASIK at an International Meeting on 7/1/2009 2Health News:Public Opinion on Health Reform Stable and Supportive as Debate Heats Up, But Moveable Too 2Health News:Public Opinion on Health Reform Stable and Supportive as Debate Heats Up, But Moveable Too 3Health News:Public Opinion on Health Reform Stable and Supportive as Debate Heats Up, But Moveable Too 4Health News:New L.A. Experience Not Only Leaves You Feeling Good but Looking Great 2Health News:RNA snippet suppresses spread of aggressive breast cancer 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: